Abstract Current therapy for glioblastoma multiforme (GBM) is largely ineffective, with nearly universal tumor recurrence. The failure of current therapy is primarily due to the lack of approaches for the efficient delivery of therapeutics to diffuse tumors in the brain. In our prior study, we developed brain-penetrating nanoparticles that are capable of penetrating brain tissue and distribute over clinically relevant volumes when administered via convection-enhanced delivery (CED). We demonstrated that these particles are capable of efficient delivery of chemotherapeutics to diffuse tumors in the brain, indicating that they may serve as a groundbreaking approach for the treatment of GBM. In the original study, nanoparticles in the brain were imaged using positron emission tomography (PET). However, clinical translation of this delivery platform can be enabled by engineering a non-invasive detection modality using magnetic resonance imaging (MRI). For this purpose, we developed chemistry to incorporate superparamagnetic iron oxide (SPIO) into the brain-penetrating nanoparticles. We demonstrated that SPIO-loaded nanoparticles, which retain the same morphology as nanoparticles without SPIO, have an excellent transverse (T 2 ) relaxivity. After CED, the distribution of nanoparticles in the brain (i.e., in the vicinity of injection site) can be detected using MRI and the long-lasting signal attenuation of SPIO-loaded brain-penetrating nanoparticles lasted over a one-month timecourse. Development of these nanoparticles is significant as, in future clinical applications, co-administration of SPIOloaded nanoparticles will allow for intraoperative monitoring of particle distribution in the brain to ensure drug-loaded nanoparticles reach tumors as well as for monitoring the therapeutic benefit with time and to evaluate tumor relapse patterns.
Introduction
Glioblastoma is most common malignant tumor of the CNS, with an incidence of approximately 18,500 cases per year [1] . Despite decades of research, glioblastoma remains one of the most deadly cancers known: overall survival has remained static since the advent of multimodal surgical/ radiation/temozolomide-based care, with long-term survivors comprising only 10 % of all patients [2-4]. Tremendous progress has been made to improve our understanding of glioblastoma biology by studying genomics [5] [6] [7] [8] [9] [10] [11] [12] , cellular hierarchy [13] [14] [15] [16] [17] [18] [19] , microenvironment [20] [21] [22] , and vasculature [23] , but none of these advances has yet been translated into verifiable survival benefit.
The difficulty in producing effective therapies is thought to be secondary to two factors: poor drug delivery and inadequate tumor sensitivity. An ideal therapy for glioblastoma, therefore, must be highly penetrative-to reach cells that have migrated into regions far from the site of tumor initiation-and must carry a payload that is effective against the cell subpopulation most responsible for tumor initiation, growth, vascularization, and therapeutic resistance. To address drug delivery challenges, we have developed brain-penetrating nanoparticles, which are in size smaller than 70 nm and in non-aggregating form, a delivery vehicle comprised of the FDA-approved copolymer poly(lactic-co-glycolic acid) (PLGA) [24] . It was previously reported that the brain interstitial spaces in normal brain are between 38 and 64 nm [25] while are 70-100 nm in regions with tumor [26] . Therefore, nanoparticles of 70 nm may accumulate in brain tumors more efficient than in normal brain tissue. We found that these nanoparticles were able to disperse over a clinically relevant volume in the brain when administered via convection-enhanced delivery (CED), which disperses agents via both convection and diffusion [27] [28] [29] [30] . When loaded with drugs with in vitro efficacy against brain cancer stem cells (BCSCs), brainpenetrating nanoparticles produce unprecedented survival in a BCSC-derived xenograft model of glioblastoma. We also developed methods for conjugation of N-(4-[
18 F]fluorobenzyl)propanamido ([ 18 F]NPB4) to the surface of nanoparticles and demonstrated that, with this modification, delivery of brain-penetrating nanoparticles in the brain can be non-invasively monitored using positron emission tomography (PET) [24] .
Non-invasive monitoring of the delivery of brain-penetrating nanoparticles in the brain is a significant development. First, it makes possible the intraoperative monitoring of particle distribution from the injection site in the brain to ensure drugloaded nanoparticles reach dispersed tumor cells. Second, it makes it possible to monitor the therapeutic benefit with time and to evaluate tumor relapse patterns with respect to the known pattern of drug delivery. While PET/CT is extremely useful in diagnostic, and other contexts, it is costly-and the short halflife of PET isotopes [31] -makes it difficult to use for monitoring of drug delivery to and in the brain.
Magnetic resonance imaging (MRI) is an attractive alternative approach, as it is routinely used clinically to visualize brain tumors before and after surgery. Therefore, functionalization of nanoparticles to allow visualization by MRI will facilitate clinical translation of brain-penetrating nanoparticles. One potential approach is to conjugate gadolinium contrast agents to the surface of nanoparticles. However, this approach has limitations for engineering nanoparticles for drug delivery to the brain: gadoliniumbased contrast agents require water access for MRI detection, so they typically need to be displayed on the surface of nanoparticles to generate sufficient signal [32] . Unfortunately, surface modification alters particle size and surface charge, potentially changing the penetrative ability of nanoparticles in brain tissue. Alternatively, superparamagnetic iron oxide (SPIO) can be used. SPIO is an excellent T 2 agent that has been experimentally demonstrated to function as a contrast agent for both therapeutic and diagnostic purposes in the mouse brain [33] , rat brain [34] , as well as in large brain of dogs [35] . Several forms of SPIO have been approved by the FDA for use in a variety of clinical settings [36] [37] [38] [39] . Unlike gadolinium contrast agents, MRI contrast due to SPIO does not depend on water access, so that SPIO can be encapsulated inside of nanoparticles without altering the physical properties of brainpenetrating nanoparticles [39] . Therefore, SPIO can be an excellent contrasts for encapsulation into brain-penetrating nanoparticles. In this study, we synthesized SPIO-loaded brain-penetrating nanoparticles, demonstrated their T 2 relaxivities and detection at low concentration by MRI after CED to the brain, and demonstrated that these nanoparticles have minimal toxicity on normal brain tissue.
Methods

Chemicals
PLGA 50:50 with an inherent viscosity of 0.59 dL/g was purchased from Lactel Polymers, Inc. (Pelham, AL, USA)) and used as received. All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Cell culture
Human glial cell line SVG p12 was purchased from ATCC (American Type Culture Collection) and were grown at 37°C incubator containing 5 % CO2 and cultured in MEM medium (Invitrogen) supplemented with 10 % fetal bovine serum (Invitrogen), 100 units/mL penicillin and 100 lg/ mL streptomycin (Invitrogen). Human neural stem cell line ReNcell CX were purchased from Millipore and were maintained in NSC Maintenance Media (Millipore) supplemented with Basic fibroblast growth factor (bFGF) and Epidermal growth factor (EGF).
Synthesis of SPIO
SPIO was synthesized as previously reported [39] . Briefly, iron acetylacetonate (Fe(acac)3) (0.396 g, 1.56 mmol), oleic acid (1.47 mL, 4.64 mmol), oleylamine (1.02 mL, 3.09 mmol), 1,2-hexadecanediol (2.005 g, 7.76 mmol) and benzyl ether (10 mL) were added to a single-neck round bottom flask equipped with a magnetic stir bar and a condenser and deoxygenated for an hour. The reaction was gradually heated to 200°C and held at that temperature for 3 h and then allowed to cool room temperature. The reaction mixture was precipitated in ethanol and centrifuged twice. Ethanol was decanted and the product was dried via nitrogen purge leaving a black powder.
Synthesis and characterization of SPIO-loaded brainpenetrating nanoparticles Nanoparticles were synthesized according to our recently published procedures with minor modifications [24] . Briefly, 100 mg of PLGA and 20 mg SPIO were dissolved in 2 mL of chloroform. The polymer/drug solution was then added dropwise to 4 mL of 2.5 % polyvinyl alcohol (PVA) as the outer aqueous phase and sonicated to form an emulsion. The emulsion was poured into a beaker containing aqueous 0.3 % (v/v) PVA and stirred at room temperature for 3 h to allow the solvent to evaporate and particles to harden. Then, the nanoparticle solution was first centrifuged at low speed (8,000 9 g for 10 min) to pellet the large particles. The supernatant was decanted and small nanoparticles were collected through high-speed ultracentrifugation (100,000 9 g for 30 min, 9 2). To prevent nanoparticle aggregation during lyophilization, trehalose was added to the final aqueous solution at a ratio of 0.5:1 (trehalose:nanoparticles) by mass immediately prior to lyophilization. The size of nanoparticles and loading of SPIO in nanoparticles were determined using the same procedures described in our recent reports [24, 39] .
Cell proliferation assay
The standard MTT assay was used to quantify the effects of nanoparticles on cell proliferation. Briefly, cells were cultured in 96-well plates (Falcon). Twenty-four hours later, cells were treated with nanoparticles in a range of 0.05-1 mg/ml. Three days after treatment, medium was removed and replaced with fresh medium containing 10 % MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Sigma) solution (4.14 mg/mL). Four hours after incubation at 37°C, all media was removed. Formazan was dissolved in DMSO and the optical density (O.D.) was measured at 590 nm. The relative inhibition on growth was determined using the following formula:
In vitro MR relaxivity measurements
Four NMR tubes containing samples of different concentrations of SPIO-loaded brain-penetrating nanoparticles (0, 0.2, 0.4 and 0.6 mg/ml) were used for relaxivity measurements. The longitudinal (R 1 ) and transverse (R 2 ) relaxation rate maps were obtained at 9.4T using an Agilent horizontalbore spectrometer (Agilent Technologies Inc., Santa Clara, CA, USA) with a 1 H radio frequency (RF) volume coil of 4 cm diameter and at 4.0T using a Bruker horizontal-bore spectrometer (Bruker, Billerica, MA, USA) with a 1 H RF volume coil of 4 cm diameter. A spin-echo pulse sequence was used at both 9.4T and 4.0T to image a single 128 9 128 slice of 2 mm thickness with a field of view (FOV) of 28 9 28 mm 2 . For R 1 mapping, 11 different repetition time (TR) values in the range of 50-8,000 ms were used, with an echo-time (TE) of 9 ms at 9.4T and 15 ms at 4.0T. For R 2 mapping at 9.4T, 12 different TE values in the range from 9 to 500 ms were used, with the same TR of 6,000 ms. For R 2 mapping at 4.0T, 11 different TE values in the range from 15 to 500 ms were used, with the same TR of 6,000 ms. The R 1 and R 2 values were calculated by fitting the time dependence of the absolute MR intensity to a single exponential function. The r 1 and r 2 relaxivities at the two magnetic fields were calculated from the slope of the linear fit of R 1 or R 2 versus SPIO concentration, [SPIO] , according to the equation:
where R 0 i (i = 1 or 2) represents water R 1 or R 2 , respectively, in the absence of the SPIO-loaded brain-penetrating nanoparticles.
CED of SPIO-loaded brain-penetrating nanoparticles
All animal experimental procedures on rats were approved by the Yale Institutional Animal Care and Use Committee (IACUC). CED was performed as previously described [24] . Sprague-Dawley rats were first anesthetized with ketamine/ xylazine. Animals were then prepped with betadine and alcohol and placed in a stereotactic frame. A linear midline incision was made and a burr hole was drilled in the skull 3 mm lateral and 0.5 mm anterior to bregma. A 26G Hamilton syringe with 28G stepdown inner cannula, was inserted to a depth of 5 mm. The tissue was allowed to equilibrate mechanically for 5 min. SPIO-loaded nanoparticles in PBS were infused continuously at a rate of 0.667 lL/min, which was selected based on our previous studies [24, 40] . Following infusion, the syringe was left in place for 5 min, after which it was removed. The burr hole was filled with bone wax (Lukens, Reading PA), the scalp was closed with surgical staples, and the rat was removed to a clean cage with free access to food and water mixed with ibuprofen for analgesia.
In vivo MR image acquisition and analysis
Immediately after initial CED of SPIO-containing brainpenetrating nanoparticles, the animals (n = 4) were artificially ventilated (70 % N 2 O, 30 % O 2 ) and kept under 1.5 % isoflurane anesthesia. The spin-echo MR datasets were obtained using the 4.0T Bruker horizontal-bore spectrometer (Bruker, Billerica, MA, USA) with a 1 H RF surface coil of 2.5 cm diameter, positioned on top of the animal head. 16 coronal slices of 128 9 128 resolution and 1 mm thickness were acquired using a FOV of 32 9 32 mm 2 , a TR of 6 s and eight different TE values in the range from 15 to 115 ms, resulting in an in-plane resolution of 250 9 250 lm 2 . The T 2 maps were obtained in Matlab (MathWorks, Inc., Natick, MA, USA) by fitting the absolute MR intensity versus TE in each voxel to a single exponential function. Measurement of SPIO volume, V d , was obtained from both spin-echo images and T 2 maps using BioImage Suite (http://www.bioimagesuite.org/) as follows. First the original spin-echo images and the T 2 maps were resampled to 200 lm isotropic resolution. Next, each spin-echo image intensity was normalized to its maximum value to provide similar intensity threshold for each dataset. Finally, the 3D volume occupied by the SPIO nanoparticles, V d , was calculated at each TE using four intensity threshold values (15, 20, 25 and 30 %) . In addition, V d was also estimated from the T 2 maps. In this case, the volume was given by the regions of the brain with T 2 \ 80 ms. The lifetime s of the SPIO nanoparticles in the rat brain, was estimated from the exponential decrease of V d /V i over time (t) according to:
where (V d /V i ) 0 represents the ratio between the volume V d immediately after the CED of SPIO-containing brain-penetrating nanoparticles (day 0) and the injected volume V i .
Results
Characterization of SPIO-loaded brain-penetrating nanoparticles
SEM of SPIO-loaded brain-penetrating nanoparticles showed that nanoparticles were approximately 68 ± 6 nm diameter and morphologically spherical (Fig. 1a, b) , consistent with previously published reports [24] . To characterize these nanoparticles in terms of MR relaxivity properties, we conducted R 1 and R 2 relaxation rate measurements of water signal at various SPIO concentrations, at two different magnetic field strengths, 9.4T and 4.0T. The r 1 and r 2 relaxivities were calculated from the slope of the linear fit of R 1 (Fig. 1c) and R 2 (Fig. 1d) versus SPIO concentration according to Eq. 1 (Table 1 ). The r 1 values are small at both field strengths, 0.003 ± 0.002 s -1 mg -1 ml at 9.4T and 0.006 ± 0.005 s -1 mg -1 ml at 4.0T (Fig. 1c) , indicating that the SPIO-loaded brain-penetrating nanoparticles are very weak longitudinal (T 1 ) relaxation agents. In contrast, the r 2 relaxivities are high, 236 ± 10 s -1 mg -1 ml at 9.4T and 202 ± 21 s -1 mg -1 ml at 4.0T (Fig. 1d ). These r 2 relaxivities are comparable to previously published values [39] and suggest these SPIO-loaded brain-penetrating nanoparticles as excellent transverse (T 2 ) relaxation agents. We previously found that what enables SPIO-loaded brainpenetrating nanoparticles to be superparamagnetic agent is the heavy loading of paramagnetic iron oxide per nanocarrier, as nanoparticles without SPIO did not produce MRI signal [39] . Therefore, in the rest of this study, we did not evaluate nanoparticles without SPIO encapsulation.
SPIO-loaded brain-penetrating nanoparticles distribute over a large volume
We sought to assess the dose-dependency of the volume occupied by the SPIO-loaded brain-penetrating nanoparticles delivered using CED. Immediately after CED of 20 ll of fluid containing SPIO nanoparticles, spin-echo MR images at various TE were acquired at 4.0T at three different SPIO doses, 0.02 mg, 0.1 mg and 0.5 mg, injected in three different animals ( Fig. 2a-c) . Using these images, T 2 maps were also generated ( Fig. 2d-f) . The hypointensity observed in the right caudate is due to the presence of the SPIO-loaded brain-penetrating nanoparticles. The measured V d depends on the dose injected, TE and the intensity threshold value used (Supplementary Fig. 1 ). V d increases with the SPIO dose at the same TE and threshold value. At the same TE, V d increases with increased threshold value, for all three doses investigated. However, V d increases with TE (at the same threshold value) only at 0.02 mg and 0.1 mg doses, while at 0.5 mg the volume remained almost unchanged with increasing TE. V d was also measured using the T 2 maps (Fig. 2d-f) . In this case, V d was defined as the volume for which T 2 \ 80 ms and the calculated values were 50 ll at 0.02 mg, 71 ll at 0.1 mg and 76 ll at 0.5 mg, which are similar to V d values calculated using the spin-echo images at higher echo times, TE [ 80 ms ( Supplementary Fig. 1 ), where the MR contrast is maximized by longer TE. Examples of 3D distributions of the SPIO nanoparticles at 4.0T are shown in Supplementary  Fig. 2 for the three doses investigated, at 30 % intensity threshold and a TE of 72 ms.
The SPIO volume of distribution, V d , and V d /V i (where V i = 20 ll represents the injected SPIO volume) are properties determined by size and the electrochemical surface of the brain-penetrating nanoparticles [24] . Using V d estimation from the T 2 maps, the calculated V d /V i values were 2.5, 3.6 and 3.8 for an SPIO dose of 0.02 mg, 0.1 mg and 0.5 mg, respectively. The V d /V i values obtained using spin-echo MR images at TE of 72 ms and 30 % intensity threshold were 2.3, 3.7 and 4.6 for an SPIO dose of 0.02 mg, 0.1 mg and 0.5 mg, respectively.
SPIO-loaded brain-penetrating nanoparticles produce long-lasting MR signal attenuation
Two different doses of SPIO-loaded brain-penetrating nanoparticles, 0.5 mg in 20 ll and 0.25 mg in 10 ll, were infused intracranially using CED in two different rats for each dose and evaluated over a four-week period using MR imaging. Examples of MR images obtained from a rat infused with 0.5 mg in 20 ll are shown in Fig. 3 . For this animal, using the time dependence of V d /V i given by Eq. 2, we calculated a lifetime s = 89 ± 9 days ( Supplementary Fig. 3,   circles) . Using the V d /V i values from all 4 animals investigated, we calculated an average V d /V i value at different times (3, 7, 14, 21 and 28 days) during the four-week period ( Supplementary Fig. 3 ). The average V d /V i value immediately after the infusion (day 0) was 3.41 ± 0.15. Interestingly, the V d /V i values from all 4 animals investigated were very similar at all time-points (less than 10 % standard deviation for each time-point) and were independent of injected volume V i (Supplementary Fig. 3 ). A lifetime s = 65 ± 11 days was calculated from the non-linear fit of the time-dependence of the average V d /V i values according to Eq. 2, shown with a continuous line in Supplementary Fig. 3 .
SPIO-loaded brain-penetrating nanoparticles are nontoxic
At the end of longitudinal imaging experiments, the rats which received a total SPIO dose of 0.5 mg in 20 ll were sacrificed and the brain was harvested for blinded histologic analysis (Fig. 4) . Tissue is notably unremarkable at low and medium magnifications. Focusing on white matter tracts at highest magnification, yellow-stained macrophages are noted, indicating likely cellular uptake of SPIO Fig. 1 Morphologic and MR characterization of SPIO-loaded brainpenetrating nanoparticles. Oleic acid-and oleylamine-coated SPIO were loaded into PLGA brain-penetrating nanoparticles and evaluated using scanning electron microscope (SEM) (a). Diameter measurements for the nanoparticle population were obtained using ImageJ (b). Measurements of the SPIO-loaded brain-penetrating nanoparticles' effect on water relaxation at two different magnetic field strengths (4.0 T and 9.4 T), indicate that these nanoparticles are not very efficient T 1 relaxation agents (c) but excellent T 2 relaxation agents (d). Moreover, these measurements indicate that there are no significant differences between the SPIO effects on water relaxation at the two magnetic fields investigated. The longitudinal r 1 and transverse r 2 relaxivities of these nanoparticles were calculated from the linear fit according to Eq. 1 and are indicated in Table 1 . Note that at 4.0T, the minimum TE possible was 15 ms (due to hardware limitations) and thus for relaxation rates R 2 [ 100 s -1 , the MR signal decreases to less than 25 % of the maximum value and the measurement of the relaxation rates becomes unreliable Table 1 Longitudinal (r 1 ) and transverse (r 2 ) relaxivities for SPIO nanoparticles at 9.4T and 4.0T or SPIO-loaded particles. We further tested SPIO-loaded brain-penetrating nanoparticles on normal human glial cell line SVG p12 and normal human neural stem cell line
ReNcell CX and found they had limited toxicity on both cells ( Supplementary Fig. 4 ). This is an expected finding and has previously been described [34] . Fig. 1 ). Moreover, using the T 2 maps to estimate V d (defined in this case as the volume for which T 2 \ 80 ms and indicated at the bottom right side of each T 2 map) gives similar estimations as when using the spin-echo images at higher echo times (TE [ 80 ms), where the MR contrast is maximized by longer TE Fig. 3 ). An exponential fit of V d /V i as function of time for this animal indicate a lifetime s = 89 ± 9 days according to Eq. 2
Discussion
The combination of the brain-penetrating nanoparticle delivery system and a BCSC-targeted small molecule agent has previously been shown to increase survival in a BCSCderived rat xenograft model of glioblastoma [24] . In this previous work, the nanoparticles were surface modified with a positron-emitting isotope, allowing visualization of the nanoparticles by PET imaging: the infused brainpenetrating nanoparticles (*70 nm diameter) distribute over a volume 8-fold larger than slightly larger nanoparticles (*150 nm diameter) of the same composition. However, clinical translation and, ultimately, clinical utility will be aided by lowering the cost, radiation, and transience of imaging modality. Therefore, functionalizing nanoparticles for MRI is important for translating these nanoparticles for future clinical applications. In this study, we developed methods to synthesize SPIOloaded brain-penetrating nanoparticles. We demonstrated that these nanoparticles have an excellent transverse relaxivity r 2 , which is higher than 200 s -1 mg -1 ml at both 4.0T and 9.4T (Table 1) and consistent with previously measured values [39] . We performed the rest of the study at 4.0T, which represents the closest clinical field strength available, to ensure that the results from this study are clinically relevant and translatable. We found that administration of SPIO-loaded nanoparticles at a concentration of 5 mg/ml (0.1 mg in 20 ll) was sufficient to monitor their distribution in the brain, as the V d estimations by MR imaging at this concentration aligned with these determined using microscopy or PET signal [24] . We also found that the strong MRI signal from the SPIO-loaded brainpenetrating nanoparticles lasted over a long period, suggesting that a single administration of brain-penetrating nanoparticles allows controlled release of cargo agents over long time periods. The T 2 contrast derived from SPIOloaded brain-penetrating nanoparticles is not dependent on SPIO release from brain-penetrating nanoparticles, as free SPIO released from brain-penetrating nanoparticles is cleared rapidly enough to exert no significant effect on T 2 weighted MR images [41] . Therefore, SPIO contained within brain-penetrating nanoparticles is the sole source of MR contrast in this system. As SPIO-loaded nanoparticles have minimal toxicity and have the same physical properties, including the morphology, size and surface property, as nanoparticles without SPIO, we speculate that a small amount (*5 mg/ml) of these particles can be co-administered with a relatively larger amount (up to 300 mg/ml) of drug-loaded nanoparticles to enable monitoring the delivery using MRI in future clinical application.
Numerous SPIO formulations have been developed and evaluated in the laboratory, with at least three having been tested in humans as diagnostic aides. The most commonly described formulations-ferumoxides (Feridex; Berlex Laboratories, Wayne, NJ, USA) [36] , ferumoxytol (Advanced Magnetics, Inc., Lexington, MA, USA) [37] , and ferumoxtran-10 (Combidex; Advanced Magnetics, Inc., Lexington, MA, USA) [38] -have been tested domestically and abroad as intravascular contrast agents in wideranging applications including stroke [42] , inflammatory and autoimmune disease [43] , and, most recently, malignancy [44] . Combidex and Feridex are two dextran-coated SPIO formulations tested in humans. Different from Combidex-ferumoxtran-10, which is a completely coated iron oxide particle with diameter between 20 and 50 nm, Feridex -ferumoxide-is an incompletely dextran-coated SPIO particle with diameter 60-185 nm. In contrast, Ferumoxytol is an ultrasmall (*30 nm) SPIO formulation incompletely coated with semisynthetic carbohydrate designed to remain inside the intravascular space [37] . Our preparations of SPIO-loaded brain-penetrating nanoparticles are unique in their functionality, as we demonstrate in this report. This long experience with the safety of SPIO in humans, coupled with the even longer history of use of PLGA in FDA-approved products, suggests that our preparations will also be safe and non-toxic.
In summary, we have developed techniques to synthesize and deliver PLGA brain-penetrating nanoparticles and monitor their distribution in the brain using MRI. In future clinical applications, non-invasive monitoring of the delivery of brain-penetrating nanoparticles in the brain can be potentially achieved through co-administration of independently synthesized SPIO-and drug-containing brain-penetrating nanoparticle populations that are otherwise identical. Because of the excellent safety profiles of PLGA and SPIO, this novel drug delivery platform can have an immediate impact on monitoring of treatment in patients with GBM.
